Aureobasidin A |
رقم الكتالوجGC62854
One-Click Copy Product Info
|
Aureobasidin A (Basifungin) ، ديسبسيبتيد دوري ، هو مضاد حيوي مضاد للفطريات
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 127785-64-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Aureobasidin A is an orally active cyclic peptide antibiotic[1]. Aureobasidin A is an inhibitor of inositol phosphorylating ceramide synthase AUR1[2]. Aureobasidin A has antifungal and antiparasitic activities[3, 4].
In vitro, Aureobasidin A (20ng/mL) treatment of Candida albicans SC5314 for 24h completely inhibited the growth of the strain[5]. Aureobasidin A (5, 10μg/mL) treated with Toxoplasma gondii tachyzoites for 24h significantly inhibited the proliferation of Toxoplasma gondii tachyzoites[6].
In vivo, Aureobasidin A (20, 40mg/kg) was used orally and subcutaneously to treat mice with systemic Candida infection, producing good therapeutic effects, which were superior to fluconazole and amphotericin B[7].
References:
[1] Teymuri M, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans[J]. Bioorganic & Medicinal Chemistry Letters, 2021, 41: 128013.
[2] Katsuki Y, Yamaguchi Y, Tani M. Overexpression of PDR16 confers resistance to complex sphingolipid biosynthesis inhibitor aureobasidin A in yeast Saccharomyces cerevisiae[J]. FEMS microbiology letters, 2018, 365(3): fnx255.
[3] Alimehr S, Shams-Ghahfarokhi M, Razzaghi Abyaneh M. Antifungal activity of Aureobasidin a in combination with Fluconazole against fluconazole-resistant Candida albicans[J]. Infection Epidemiology and Microbiology, 2020, 6(4): 285-291.
[4] Tanaka A K, Valero V B, Takahashi H K, et al. Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A[J]. Journal of Antimicrobial Chemotherapy, 2007, 59(3): 487-492.
[5] Zheng L, Xu Y, Dong Y, et al. Chromosome 1 trisomy confers resistance to aureobasidin A in Candida albicans[J]. Frontiers in Microbiology, 2023, 14: 1128160.
[6] Alqaisi A Q I, Mbekeani A J, Llorens M B, et al. The antifungal Aureobasidin A and an analogue are active against the protozoan parasite Toxoplasma gondii but do not inhibit sphingolipid biosynthesis[J]. Parasitology, 2018, 145(2): 148-155.
[7] TAKESAKO K, KURODA H, INOUE T, et al. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic[J]. The Journal of antibiotics, 1993, 46(9): 1414-1420.
| Cell experiment [1]: | |
Cell lines | C. albicans lab strain SC5314 |
Preparation Method | C. albicans lab strain SC5314 was grown in YPD broth or on YPD plates supplemented with 0-20ng/mL Aureobasidin A. Optical density at 595nm was measured every 15min for 24h at 37°C using a Tecan plate reader. 3μL of 10-fold serial dilutions were spotted on YPD plates. The plates were incubated at 37°C for 48h then photographed. |
Reaction Conditions | 0-20ng/mL; 24h、48h |
Applications | In the liquid medium, growth in the presence of 5ng/mL or 10ng/mL of Aureobasidin A did not significantly inhibit growth. 20ng/mL of Aureobasidin A completely inhibited growth. On the plates, growth was also inhibited by 20ng/ml of Aureobasidin A. |
| Animal experiment [2]: | |
Animal models | ICR mice |
Preparation Method | Groups of mice were treated with Aureobasidin A, Fluconazole or Amphotericin B. Aureobasidin A or Fuconazole was administered orally once daily from day-0 to -6 at the dose of 20mg/kg and from day-3 to -9 at the dose of 40mg/kg. Amphotericin B was given subcutaneously once daily from day-3 to -9 at the dose of 5mg/kg. On day-0 and -4, -7, -10, -14, and -21 after infection, some mice in each group were sacrificed and their kidneys were removed aseptically. The removed kidneys were sectioned through the middle and the exposed surface was stamped on SD agar plates for inoculation. All of the plates were incubated at 30°C for 2 days and the number of visibly growing colonies of C. albicans were Whenfive counted. |
Dosage form | 20、40mg/kg; p.o. |
Applications | Aureobasidin A shows low toxicity and good efficacy against murine candidiasis. Aureobasidin A also prolongs survival days of infected mice by oral treatment, even when the treatment was started after completion of infection. |
References: | |
| Cas No. | 127785-64-2 | SDF | |
| Formula | C60H92N8O11 | M.Wt | 1101.42 |
| الذوبان | DMSO : 100 mg/mL (90.79 mM; Need ultrasonic) | Storage | Store at -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 907.9 μL | 4.5396 mL | 9.0792 mL |
| 5 mM | 181.6 μL | 907.9 μL | 1.8158 mL |
| 10 mM | 90.8 μL | 454 μL | 907.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)